Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30162631 | 1.00 | KMT2A (1.00) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL8735682 | 0.82 | KMT2A (0.70) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL681071 | 0.82 | KMT2A (0.70) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL4358158 | 0.82 | KMT2A (0.70) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL120913 | 0.82 | KMT2A (0.70) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL29518150 | 0.82 | KMT2A (0.70) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL13067261 | 0.82 | KMT2A (0.70) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL3954275 | 0.79 | KMT2A (0.66) | KMT2ANPSR1ALDH1A1MAPTGLA | |
| SCHEMBL27591796 | 0.79 | KMT2A (0.66) | KMT2ANPSR1ALDH1A1GFERMAPT | |
| SCHEMBL3640530 | 0.78 | KMT2A (0.65) | KMT2ANPSR1ALDH1A1MAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240191028-A1 | COMPOSITION FOR MANUFACTURING POLYIMIDE FILM AND POLYIMIDE FILM FOR FLEXIBLE METAL CLAD LAMINATE MANUFACTURED USING THE SAME | NEXFLEX CO., LTD. (KR) | 2024-06-13 | — | — | US | claimed |
| WO-2023200025-A1 | COMPOSITION FOR PRODUCING POLYIMIDE FILM AND POLYIMIDE FILM FOR FLEXIBLE METAL CLAD LAMINATE PRODUCED USING SAME | 주식회사 넥스플렉스 | 2023-10-19 | — | — | WO | claimed |
| CN-114957215-B | Methylene bridged quinoline and 1,2, 3-triazole diheterocyclic compound and preparation method and application thereof | 渤海大学 | 2023-03-21 | — | — | CN | claimed |
| CN-114957215-A | Methylene bridged quinoline and 1,2, 3-triazole diheterocyclic compound and preparation method and application thereof | 渤海大学 | 2022-08-30 | — | — | CN | claimed |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240191028-A1 | COMPOSITION FOR MANUFACTURING POLYIMIDE FILM AND POLYIMIDE FILM FOR FLEXIBLE METAL CLAD LAMINATE MANUFACTURED USING THE SAME | NEXFLEX CO., LTD. (KR) | 2024-06-13 | — | — | US | disclosed |
| EP-4362978-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023200025-A1 | COMPOSITION FOR PRODUCING POLYIMIDE FILM AND POLYIMIDE FILM FOR FLEXIBLE METAL CLAD LAMINATE PRODUCED USING SAME | 주식회사 넥스플렉스 | 2023-10-19 | — | — | WO | disclosed |
| CN-114957215-B | Methylene bridged quinoline and 1,2, 3-triazole diheterocyclic compound and preparation method and application thereof | 渤海大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-114957215-B | Methylene bridged quinoline and 1,2, 3-triazole diheterocyclic compound and preparation method and application thereof | 渤海大学 | 2023-03-21 | — | — | CN | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278222-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-01-05 | — | — | WO | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| CN-1268942-A | Sulfonamide compounds and medicinal use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-RE34722-E | Antiulcer agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| US-4578381-A | ANTIULCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | KMT2A 1218/4885NPSR1 463/4885ALDH1A1 570/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | KMT2A 1587/4885NPSR1 1699/4885ALDH1A1 1067/4885 |
| US-20240287022-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | KMT2A 2905/4885NPSR1 951/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.